Brokerages Set Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Price Target at $57.50

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has been given an average recommendation of “Moderate Buy” by the six brokerages that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $57.50.

COLL has been the subject of several recent analyst reports. Wall Street Zen cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 25th. Truist Financial raised shares of Collegium Pharmaceutical to a “strong-buy” rating in a report on Monday, June 15th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Collegium Pharmaceutical in a report on Monday, July 6th. Finally, Zacks Research downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th.

Institutional Trading of Collegium Pharmaceutical

A number of institutional investors have recently bought and sold shares of COLL. Group One Trading LLC acquired a new position in shares of Collegium Pharmaceutical during the 4th quarter worth $28,000. Caitong International Asset Management Co. Ltd grew its stake in Collegium Pharmaceutical by 205.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock valued at $29,000 after acquiring an additional 427 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in Collegium Pharmaceutical by 42.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 418 shares during the last quarter. Kemnay Advisory Services Inc. purchased a new position in Collegium Pharmaceutical during the 4th quarter valued at about $61,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Collegium Pharmaceutical by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock valued at $71,000 after acquiring an additional 318 shares in the last quarter.

Collegium Pharmaceutical Price Performance

Collegium Pharmaceutical stock opened at $35.73 on Thursday. The company has a market cap of $1.16 billion, a P/E ratio of 17.52 and a beta of 0.73. Collegium Pharmaceutical has a one year low of $29.70 and a one year high of $50.79. The business has a fifty day moving average of $34.95 and a two-hundred day moving average of $37.24. The company has a debt-to-equity ratio of 2.47, a quick ratio of 1.62 and a current ratio of 1.71.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share for the quarter, topping analysts’ consensus estimates of $1.52 by $0.24. The business had revenue of $193.52 million for the quarter, compared to analysts’ expectations of $184.47 million. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The business’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same period in the prior year, the company posted $1.49 EPS. As a group, analysts predict that Collegium Pharmaceutical will post 6.76 earnings per share for the current fiscal year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.